Advertisement

Volume 129, Issue 20

Cover Figure: Inhibition of Hsp90 destabilizes Ezh2 protein and reduces murine GVHD. See the article by Huang et al.

WASHINGTON, May 17, 2017 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Monitoring of childhood ALL using BCR-ABL1 genomic breakpoints identifies a subgroup with CML-like biology
Hovorkova and colleagues report that discordant results of DNA-based minimal residual disease monitoring of BCR-ABL1 and immunoglobulin/T-cell receptor gene rearrangements suggest that an unexpectedly high percentage of childhood acute lymphoblastic leukemias may in fact be chronic myeloid leukemias in lymphoid blast crisis.

Thrombophilia risk is not increased in children after perinatal stroke
In a study presented in this month’s CME article, Curtis et al performed extensive thrombophilia testing on a large cohort of children with perinatal stroke. They demonstrate that these children have the same rate of thrombophilic mutations as the normal population.

Lower levels of vitamin A are associated with increased gastrointestinal graft-versus-host disease in children
Lounder and colleagues demonstrate that children with vitamin A levels below the median have an increased incidence of gut graft-versus-host disease and a higher mortality rate than children with vitamin A levels above the median, suggesting the possibility that vitamin repletion might be a simple means of improving transplant outcomes.

Treating sickle cell disease by targeting HbS polymerization
Eaton and Bunn present strategies for targeting polymerization of sickle hemoglobin (HbS) for the treatment of sickle cell disease, progressing from an elegant outline of the biochemistry of sickling to a discussion of current therapies under study.

How I treat central venous access device–related upper extremity deep vein thrombosis
Rajasekhar and Streiff use three illustrative cases to present a practical approach to the evaluation and treatment of upper extremity deep vein thrombosis associated with central venous access devices.

Hsp90 inhibition destabilizes Ezh2 protein in alloreactive T cells and reduces graft-versus-host disease in mice
Huang and colleagues demonstrate that while Ezh2 inhibition does not block graft-versus-host disease (GVHD), destabilization of Ezh2 by inhibition of Hsp90 reduces GVHD without impairing graft-versus-leukemia in mice.

 

This week's complete table of contents

Why Submit to Blood?

 


 

Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.